Nixon NA, et al. – The prime focus of this research is to describe the drug development timeline and attrition rate of different drug classes for common cancer disease sites. Results of this study suggested that overall oncologic drug attrition rates remain high, and drugs are more likely to fail in later–stage clinical trials. The refinement of early–phase trial design might permit the range of drugs that are more likely to succeed in the phase 3 setting.